King's College London

Research portal

Are the risks of treatment to cure a child with severe sickle cell disease too high?

Research output: Contribution to journalComment/debate

Standard

Are the risks of treatment to cure a child with severe sickle cell disease too high? / de Montalembert, Mariane; Brousse, Valentine; Chakravorty, Subarna; Pagliuca, Antonio; Porter, John; Telfer, Paul; Vora, Ajay; Rees, David C.

In: BMJ (Clinical research ed.), Vol. 359, j5250, 2017.

Research output: Contribution to journalComment/debate

Harvard

de Montalembert, M, Brousse, V, Chakravorty, S, Pagliuca, A, Porter, J, Telfer, P, Vora, A & Rees, DC 2017, 'Are the risks of treatment to cure a child with severe sickle cell disease too high?', BMJ (Clinical research ed.), vol. 359, j5250. https://doi.org/10.1136/bmj.j5250

APA

de Montalembert, M., Brousse, V., Chakravorty, S., Pagliuca, A., Porter, J., Telfer, P., ... Rees, D. C. (2017). Are the risks of treatment to cure a child with severe sickle cell disease too high? BMJ (Clinical research ed.), 359, [j5250]. https://doi.org/10.1136/bmj.j5250

Vancouver

de Montalembert M, Brousse V, Chakravorty S, Pagliuca A, Porter J, Telfer P et al. Are the risks of treatment to cure a child with severe sickle cell disease too high? BMJ (Clinical research ed.). 2017;359. j5250. https://doi.org/10.1136/bmj.j5250

Author

de Montalembert, Mariane ; Brousse, Valentine ; Chakravorty, Subarna ; Pagliuca, Antonio ; Porter, John ; Telfer, Paul ; Vora, Ajay ; Rees, David C. / Are the risks of treatment to cure a child with severe sickle cell disease too high?. In: BMJ (Clinical research ed.). 2017 ; Vol. 359.

Bibtex Download

@article{662c6a7597f5452ca71342c276ba1ee6,
title = "Are the risks of treatment to cure a child with severe sickle cell disease too high?",
abstract = "Key messagesCurative treatment for sickle cell disease is potentially available to all patients using haematopoietic stem cell transplantation from alternative donors, but the risks of these procedures are very highWe don’t know when these high risk transplants should be offered to children or how parents should be counselled to give appropriate consentIn high income countries, non-transplant treatments are being developed for sickle cell disease that are likely to improve prognosisWe need to develop safer transplants and to explore the ethics of offering high risk procedures to children with sickle cell disease and other chronic conditions",
keywords = "Anemia, Sickle Cell/therapy, Child, Hematopoietic Stem Cell Transplantation/adverse effects, Histocompatibility, Humans, Randomized Controlled Trials as Topic/methods, Risk Assessment, Tissue Donors",
author = "{de Montalembert}, Mariane and Valentine Brousse and Subarna Chakravorty and Antonio Pagliuca and John Porter and Paul Telfer and Ajay Vora and Rees, {David C}",
year = "2017",
doi = "10.1136/bmj.j5250",
language = "English",
volume = "359",
journal = "BMJ (Clinical research ed.)",
issn = "1756-1833",
publisher = "BMJ Publishing Group",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Are the risks of treatment to cure a child with severe sickle cell disease too high?

AU - de Montalembert, Mariane

AU - Brousse, Valentine

AU - Chakravorty, Subarna

AU - Pagliuca, Antonio

AU - Porter, John

AU - Telfer, Paul

AU - Vora, Ajay

AU - Rees, David C

PY - 2017

Y1 - 2017

N2 - Key messagesCurative treatment for sickle cell disease is potentially available to all patients using haematopoietic stem cell transplantation from alternative donors, but the risks of these procedures are very highWe don’t know when these high risk transplants should be offered to children or how parents should be counselled to give appropriate consentIn high income countries, non-transplant treatments are being developed for sickle cell disease that are likely to improve prognosisWe need to develop safer transplants and to explore the ethics of offering high risk procedures to children with sickle cell disease and other chronic conditions

AB - Key messagesCurative treatment for sickle cell disease is potentially available to all patients using haematopoietic stem cell transplantation from alternative donors, but the risks of these procedures are very highWe don’t know when these high risk transplants should be offered to children or how parents should be counselled to give appropriate consentIn high income countries, non-transplant treatments are being developed for sickle cell disease that are likely to improve prognosisWe need to develop safer transplants and to explore the ethics of offering high risk procedures to children with sickle cell disease and other chronic conditions

KW - Anemia, Sickle Cell/therapy

KW - Child

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Histocompatibility

KW - Humans

KW - Randomized Controlled Trials as Topic/methods

KW - Risk Assessment

KW - Tissue Donors

U2 - 10.1136/bmj.j5250

DO - 10.1136/bmj.j5250

M3 - Comment/debate

C2 - 29170154

VL - 359

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

SN - 1756-1833

M1 - j5250

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454